A justice-based argument for including sickle cell disease in CRISPR/Cas9 clinical research

CRISPR/Cas9 is quickly becoming one of the most influential biotechnologies of the last five years. Clinical trials will soon be underway to test whether CRISPR/Cas9 can edit away the genetic mutations that cause sickle cell disease (SCD). This article will present the background of CRISPR/Cas9 gene...

Full description

Saved in:  
Bibliographic Details
Main Author: Baffoe-Bonnie, Marilyn S. (Author)
Contributors: Chan, Berman (Bibliographic antecedent)
Format: Electronic Article
Language:English
Check availability: HBZ Gateway
Journals Online & Print:
Drawer...
Fernleihe:Fernleihe für die Fachinformationsdienste
Published: Wiley-Blackwell [2019]
In: Bioethics
Year: 2019, Volume: 33, Issue: 6, Pages: 661-668
IxTheo Classification:NCH Medical ethics
NCJ Ethics of science
Further subjects:B Biotechnology
B CRISPR / Cas9
B Distributive Justice
B Sickle cell disease
B Clinical Trials
B benefit-sharing
Online Access: Volltext (Verlag)
Volltext (doi)

MARC

LEADER 00000caa a22000002 4500
001 1727506030
003 DE-627
005 20230426130552.0
007 cr uuu---uuuuu
008 200820s2019 xx |||||o 00| ||eng c
024 7 |a 10.1111/bioe.12589  |2 doi 
035 |a (DE-627)1727506030 
035 |a (DE-599)KXP1727506030 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 1  |2 ssgn 
100 1 |a Baffoe-Bonnie, Marilyn S.  |e VerfasserIn  |4 aut 
245 1 2 |a A justice-based argument for including sickle cell disease in CRISPR/Cas9 clinical research 
264 1 |c [2019] 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
520 |a CRISPR/Cas9 is quickly becoming one of the most influential biotechnologies of the last five years. Clinical trials will soon be underway to test whether CRISPR/Cas9 can edit away the genetic mutations that cause sickle cell disease (SCD). This article will present the background of CRISPR/Cas9 gene editing and SCD, highlighting research that supports the application of CRISPR/Cas9 to SCD. While much has been written on why SCD is a good biological candidate for CRISPR/Cas9, less has been written on the ethical implications of including SCD in CRISPR/Cas9 research. This article will argue that there is a strong case in favor of including SCD. Three benefits are achieving distributive justice in research, continuing to repair the negative relationship between patients with SCD and the health-care system, and benefit-sharing for those who do not directly participate in CRISPR/Cas9 research. Opponents will argue that SCD is a risky candidate, that researchers will not find willing participants, and that the burden of SCD is low. Of this set of arguments, the first gives pause. However, on balance, the case in favor of including SCD in CRISPR/Cas9 research is stronger than the case against. Ultimately, this article will show that the historic and sociopolitical injustices that impede progress in treating and curing SCD can be alleviated through biotechnology. 
601 |a Argumentation 
650 4 |a CRISPR/Cas9 
650 4 |a benefit-sharing 
650 4 |a Biotechnology 
650 4 |a Clinical Trials 
650 4 |a Distributive Justice 
650 4 |a Sickle cell disease 
652 |a NCH:NCJ 
700 1 |a Chan, Berman  |e VerfasserIn des Bezugswerks  |4 ant 
773 0 8 |i Enthalten in  |t Bioethics  |d Oxford [u.a.] : Wiley-Blackwell, 1987  |g 33(2019), 6, Seite 661-668  |h Online-Ressource  |w (DE-627)271596708  |w (DE-600)1480658-7  |w (DE-576)078707986  |x 1467-8519  |7 nnns 
773 1 8 |g volume:33  |g year:2019  |g number:6  |g pages:661-668 
787 0 8 |i Kritik in  |a Chan, Berman  |t Improving the justice-based argument for conducting human gene editing research to cure sickle cell disease  |d 2020  |w (DE-627)1727465946 
856 4 0 |u https://onlinelibrary.wiley.com/doi/abs/10.1111/bioe.12589  |x Verlag 
856 |u https://doi.org/10.1111/bioe.12589  |x doi  |3 Volltext 
936 u w |d 33  |j 2019  |e 6  |h 661-668 
951 |a AR 
ELC |a 1 
ITA |a 1  |t 1 
LOK |0 000 xxxxxcx a22 zn 4500 
LOK |0 001 3741282588 
LOK |0 003 DE-627 
LOK |0 004 1727506030 
LOK |0 005 20210928163909 
LOK |0 008 200820||||||||||||||||ger||||||| 
LOK |0 040   |a DE-Tue135  |c DE-627  |d DE-Tue135 
LOK |0 092   |o n 
LOK |0 852   |a DE-Tue135 
LOK |0 852 1  |9 00 
LOK |0 935   |a ixzs  |a ixzo 
LOK |0 936ln  |0 1550736558  |a NCH 
LOK |0 936ln  |0 1550736582  |a NCJ 
ORI |a SA-MARC-ixtheoa001.raw